department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

IDEAYA Biosciences, Inc. ($IDYA) · pharmadog

PUBLIC COMPANY

$IDYAIDEAYA Biosciences, Inc.

South San Francisco, CA, USupdated 1mo ago

SEC EDGAR ↗Yahoo Finance ↗

community read0 votes

pipeline

9

marketed

0

phase 3

1

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(9)

pipeline depth9 products

1Preclinical3Phase 14Phase 21Phase 3

Metastatic Uveal Melanoma

Phase 2

IDE-161

Colon Cancer

Endometrial Cancer

Adenoid Cystic Carcinoma (ACC)

Neuroendocrine Tumors

Castration-Resistant Prostate Cancer (CRPC)

Esophageal Squamous Cell Carcinoma (ESCC)

Pancreatic Cancer

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view IDEAYA Biosciences, Inc. jobs →

News

no news has mentioned this company yet

identifiers

ticker

$IDYA

SEC CIK

0001676725

country

US

source

sec_tickers

top tags

Oncology9 Colorectal Cancer5 NSCLC5 Prostate Cancer2 Breast Cancer1

mentioned in

0news items

entity-linker matched

$IDYA

Data sources

last refreshed 52m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase1A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumorsactive not recruitingn=216
phase2A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumorsrecruitingn=160
phase1Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletionactive not recruitingn=169
phase1A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumorsrecruitingn=260
phase1A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Typesrecruitingn=150
phase2(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanomaactive not recruitingn=160
phase3Neoadjuvant Darovasertib in Primary Uveal Melanomarecruitingn=520
phase3IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanomaactive not recruitingn=420

more trials →

Insider activity

source: SEC Form 4

open-market buys + sells

Mar 2, 26BUYStein Jeffrey· director50,000 sh @ $32.96$1.65M↗

routine RSU / option mechanics (6)

Jan 30, 26grantBleharski Joshua · Chief Financial Officer170,000 sh
Jan 30, 26grantWHITE MICHAEL ANTHONY · Chief Scientific Officer190,000 sh
Jan 30, 26grantBeaupre Darrin · Chief Medical Officer175,000 sh
Jan 30, 26grantDORMAN STUART · Chief Commercial Officer155,000 sh
Jan 30, 26grantHata Yujiro S · President and CEO600,000 sh
Jan 30, 26grantSnyder Douglas B. · SVP, General Counsel130,000 sh